HemoGenyx Pharmaceuticals PLC (LON:HEMO) has entered into a collaboration agreement with Rockefeller University to use its new type of humanised mice for autoimmune disease modelling in an effort to develop new treatment for autoimmune diseases, specifically Lupus.
Under the agreement, the collaborative work will be co-led by investigators at HemoGenyx and Rockefeller with professor Alexander Tarakhovsky acting as the principal investigator for Rockefeller and Dr Vladislav Sandler acting as the principal investigator for Hemogenyx.
The biotechnology company said its directors are confident that the collaboration does not require forms of funding that would be dilutive to HemoGenyx shareholders.
Vladislav Sandler, CEO and co-founder of HemoGenyx, said: “This agreement with Rockefeller has the potential to extend our product candidate opportunities into a new and exciting area, and we would fully expect to see the work funded through future non-dilutive grant funding.”
He added: ”Shareholders can now also see the potential for the use of our technology beyond our current bone marrow transplantation focus to treat debilitating and otherwise incurable autoimmune diseases such as Lupus.”
HemoGenyx said the first stage of development work will create mice that emulate the human symptoms of Lupus, while the second stage will then focus on the development of multi-specific antibodies and cell therapies to treat the disease in these mice.
Vladislav Sandler said: “The attractiveness of our new type of humanized mice to major biotechnology companies and leading research institutes will give us further opportunities to collaborate on other disease models and specific drug development.”